© Reuters.
FRANKFURT – CureVac recently reported encouraging results from its latest COVID-19 vaccine trials, conducted in partnership with GSK. Preliminary data indicate that the vaccines, comprising a monovalent and a bivalent candidate, generated strong immune responses even at lower doses and are well tolerated.
The monovalent vaccine candidate is designed to target the spike protein of the Omicron BA.4-5 variant, while the bivalent vaccine candidate targets the spike proteins of the Omicron BA.4-5 variant and the SARS-CoV-2 virus original. These results mark a significant advance in ongoing efforts to develop effective vaccines against emerging COVID-19 variants.
As the company announces these positive results, it is also preparing for discussions about moving to a phase 3 trial. This phase is crucial to continue evaluating the effectiveness and safety of vaccine candidates at a larger scale. ladder. Moving to Phase 3 will bring vaccines closer to potential approval and availability to the public.
This article was generated and translated with the help of AI and reviewed by an editor. For more information, see our T&Cs.